Beijing Tongren Hospital

This study tests a drug called zanubrutinib combined with standard chemotherapy for people newly diagnosed with a fast-growing lymphoma (DLBCL) who have high-risk features. The goal is to see if this combo can improve remission rates and help control the disease better than curre…

This study tests a combination of three drugs (pomalidomide, an anti-PD-1 antibody, and selinexor) in people whose primary central nervous system lymphoma has come back or not responded to prior treatment. The goal is to see if this combination can shrink or eliminate tumors. Abo…

This early-phase study is testing whether two experimental drugs, finotonlimab and stapokibart, are safe and can shrink tumors in people with advanced head and neck cancer that has come back or spread. The study will include 10 adults whose cancer got worse after standard treatme…

This study tests a drug called orelabrutinib, taken alone or with another drug (CD20 antibody), in people with untreated marginal zone lymphoma. The goal is to see how well the treatment shrinks or controls the cancer. About 88 adults will take part, and the study is currently re…

This study tests a new mix of five drugs (MEPL-G) for people with a rare, aggressive lymphoma (NK/T-cell) that has triggered a dangerous overreaction of the immune system called HLH. The goal is to control both the cancer and the immune storm quickly, improving survival. About 25…

This study tests two types of special glasses designed to slow the progression of nearsightedness (myopia) in children aged 6 to 14. Participants will wear the glasses daily for one year and attend regular eye exams. The goal is to see which lens design works best and whether the…

This study tests an experimental antibody drug for people whose seasonal allergy symptoms (like sneezing, runny nose, and itchy eyes) are not controlled by standard treatments. About 120 adults will receive either the drug or a placebo, and researchers will track how well it redu…

This study looks at how high blood pressure, diabetes, and high cholesterol change the tiny blood vessels in the back of the eye. Researchers will use a special, non-invasive eye scan called OCTA to measure these changes in 300 adults. Participants will be followed for five years…